Abbott (ABT) Receives CE Mark for Next-Gen XIENCE PRIME(TM) Drug Eluting Stent
Tweet Send to a Friend
Abbott (NYSE: ABT) announced today that it has received CE Mark for its next-generation XIENCE PRIME(TM) Everolimus Eluting Coronary Stent ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
